Related references
Note: Only part of the references are listed.Nivolumab in renal cell carcinoma: latest evidence and clinical potential
Camille Mazza et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2017)
PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation
Sheema Almozyan et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy
Huan Bin Wang et al.
JOURNAL OF DIGESTIVE DISEASES (2017)
New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy
Kevin Zarrabi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer
Xiaomei Gong et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma
Steven C. Kao et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines
Toshifumi Doi et al.
ONCOLOGY REPORTS (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
PD-1/PD-L1 Pathway in Breast Cancer
Florian Schuetz et al.
ONCOLOGY RESEARCH AND TREATMENT (2017)
The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200
Muhammad Zaeem Noman et al.
ONCOIMMUNOLOGY (2017)
The function and regulation of PD-L1 in immunotherapy
Libin Guo et al.
ADMET AND DMPK (2017)
PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer
Lujun Chen et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2017)
Biomarkers of response to PD-1/PD-L1 inhibition
Saman Maleki Vareki et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
miR-142-5p regulates tumor cell PD-Ll expression and enhances anti-tumor immunity
Long Jia et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Cancer immunotherapies targeting the PD-1 signaling pathway
Yoshiko Iwai et al.
JOURNAL OF BIOMEDICAL SCIENCE (2017)
Regulation of PD-L1: a novel role of pro-survival signalling in cancer
J. Chen et al.
ANNALS OF ONCOLOGY (2016)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
P. F. Ferrucci et al.
ANNALS OF ONCOLOGY (2016)
Immune Blockade Inhibition in Breast Cancer
Ioannis A. Voutsadakis
ANTICANCER RESEARCH (2016)
Non-Small Cell Lung Cancer, PD-L1, and the Pathologist
Keith M. Kerr et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma
Curtis A. Clark et al.
CANCER RESEARCH (2016)
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Benjamin Weide et al.
CLINICAL CANCER RESEARCH (2016)
Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma
Yanyan Lou et al.
CLINICAL CANCER RESEARCH (2016)
Emerging therapeutics in refractory renal cell carcinoma
Vadim S. Koshkin et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
Junzo Hamanishi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
Weijie Ma et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes
Matthew W. Rosenbaum et al.
MODERN PATHOLOGY (2016)
Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer
Lisha Wang et al.
MOLECULAR DIAGNOSIS & THERAPY (2016)
Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade Enhanced Cancer Photodynamic Immunotherapy
Dangge Wang et al.
NANO LETTERS (2016)
miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint
Shaohua Xu et al.
NATURE COMMUNICATIONS (2016)
The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer
Lian Zhao et al.
ONCOTARGET (2016)
PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations
Andreas H. Scheel et al.
ONCOIMMUNOLOGY (2016)
The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1
Zhaohui Jin et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2016)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer
Rita Nanda et al.
CANCER RESEARCH (2015)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date
Katy K. Tsai et al.
DRUGS (2015)
Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?
Srinath Sundararajan et al.
FUTURE ONCOLOGY (2015)
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
Lieping Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Scott N. Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer In what state is this art?
Keith M. Kerr et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer
Yu Fujita et al.
MOLECULAR THERAPY (2015)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The prognostic significance of PD-L1 in bladder cancer
Yide Huang et al.
ONCOLOGY REPORTS (2015)
New immunotherapies targeting the PD-1 pathway
Jordan M. Chinai et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy
Yanping Xiao et al.
CANCER DISCOVERY (2015)
Adaptive Immune Resistance: How Cancer Protects from Immune Attack
Antoni Ribas
CANCER DISCOVERY (2015)
Clinical blockade of PD1 and LAG3-potential mechanisms of action
Linh T. Nguyen et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma
Matthew Weinstock et al.
THERAPEUTIC ADVANCES IN UROLOGY (2015)
Biochemical Signaling of PD-1 on T Cells and Its Functional Implications
Vassiliki A. Boussiotis et al.
CANCER JOURNAL (2014)
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Mohammad Atefi et al.
CLINICAL CANCER RESEARCH (2014)
Correlation of PDL1 tumor expression and treatment outcomes in patients with renal cell carcinoma (RCC) receiving tyrosine kinase inhibitors: COMPARZ study analysis.
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection
Peiyuan Lu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
Yanping Xiao et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
Limo Chen et al.
NATURE COMMUNICATIONS (2014)
EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
Wenfeng Fang et al.
ONCOTARGET (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Targeting hypoxia at the forefront of anticancer immune responses
Muhammad Zaeem Noman et al.
ONCOIMMUNOLOGY (2014)
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
Xiaofeng Jiang et al.
CLINICAL CANCER RESEARCH (2013)
A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma
Weipeng Wang et al.
HUMAN GENETICS (2013)
PD-1 Increases PTEN Phosphatase Activity While Decreasing PTEN Protein Stability by Inhibiting Casein Kinase 2
Nikolaos Patsoukis et al.
MOLECULAR AND CELLULAR BIOLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
Minmin Song et al.
PLOS ONE (2013)
Immunotherapy for colorectal cancer
Shigeo Koido et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2013)
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay et al.
CANCER DISCOVERY (2013)
Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
Daniel S. Chen et al.
CLINICAL CANCER RESEARCH (2012)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation
Nikolaos Patsoukis et al.
SCIENCE SIGNALING (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Paclitaxel Induced B7-H1 Expression in Cancer Cells via the MAPK Pathway
Wenrong Gong et al.
JOURNAL OF CHEMOTHERAPY (2011)
Cancer Immunotherapy Comes of Age
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection
Charlly Kao et al.
NATURE IMMUNOLOGY (2011)
New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies
Thean Hsiang Tan et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2010)
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
Michael R. Green et al.
BLOOD (2010)
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
Jang-June Park et al.
BLOOD (2010)
Tumor Cell Expression of Programmed Cell Death-1 Ligand 1 Is a Prognostic Factor for Malignant Melanoma
Ryosuke Hino et al.
CANCER (2010)
The Chromosomal Instability Pathway in Colon Cancer
Maria S. Pino et al.
GASTROENTEROLOGY (2010)
Microsatellite Instability in Colorectal Cancer
C. Richard Boland et al.
GASTROENTEROLOGY (2010)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF
Michael Quigley et al.
NATURE MEDICINE (2010)
MicroRNAs: Target Recognition and Regulatory Functions
David P. Bartel
CELL (2009)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
MicroRNA-513 Regulates B7-H1 Translation and Is Involved in IFN-γ-Induced B7-H1 Expression in Cholangiocytes
Ai-Yu Gong et al.
JOURNAL OF IMMUNOLOGY (2009)
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
Shawn D. Blackburn et al.
NATURE IMMUNOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
Brian T. Fife et al.
IMMUNOLOGICAL REVIEWS (2008)
The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells
Sokol Haxhinasto et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
Michal Marzec et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The AP1-dependent secretion of galectin-1 by Reed - Sternberg cells fosters immune privilege in classical Hodgkin lymphoma
Przemyslaw Juszczynski et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
PD-L1 (B7-H1) expression by urothelial carcinoma of bladder and BCG-induced granulomata - Associations with localized stage progression
Brant A. Inman et al.
CANCER (2007)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Junzo Hamanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Andrew T. Parsa et al.
NATURE MEDICINE (2007)
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer
Takeo Nomi et al.
CLINICAL CANCER RESEARCH (2007)
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Arlene H. Sharpe et al.
NATURE IMMUNOLOGY (2007)
The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
Hidetoshi Sumimoto et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors
Hazem Ghebeh et al.
NEOPLASIA (2006)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance
Changping Wu et al.
ACTA HISTOCHEMICA (2006)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses
T Shin et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer
Y Ohigashi et al.
CLINICAL CANCER RESEARCH (2005)
Structural and functional analysis of the costimulatory receptor programmed death-1
XW Zhang et al.
IMMUNITY (2004)
PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ
KA Sheppard et al.
FEBS LETTERS (2004)
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
RH Thompson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Phospholipase Cγ activates Ras on the Golgi apparatus by means of RasGRP1
TG Bivona et al.
NATURE (2003)
Cooperative B7-1/2 (CD80/CD86) and B7-DC costimulation of CD4+ T cells independent of the PD-1 receptor
T Shin et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
TJ Curiel et al.
NATURE MEDICINE (2003)
Protein kinase CK2: structure, regulation and role in cellular decisions of life and death
DW Litchfield
BIOCHEMICAL JOURNAL (2003)
Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection
H Wedemeyer et al.
JOURNAL OF IMMUNOLOGY (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Share Paper
